COMMUNIQUÉS West-GlobeNewswire

Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
04/08/2026
Partnership Expands Commercial Reach Across VA, Department of Defense and Other Federal Healthcare Systems ROSELAND, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a medical [...]
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
04/08/2026
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) ( Nasdaq: RNXT ), a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
04/08/2026
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 class CRB-913 [...]
Carbonium Core Reports Rare Earth and Critical Mineral Content in Initial Sample Assay
04/08/2026
Multi-element analysis returns elevated concentrations of both light and heavy rare earth elements, along with a broad suite of industrial metals FREDERICK, Md., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental [...]
Beacon Behavioral Partners Expands National Footprint with First Georgia Partnership
04/08/2026
Physician-led partnership deepens access to behavioral healthcare through partnership with AR Psychiatric & Counseling Center Georgia and strengthens its growing behavioral health network across the nation PLANO, [...]
Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.
04/08/2026
VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data [...]
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial [...]
Certara Reports Second Quarter 2026 Financial Results
04/08/2026
A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance [...]
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
04/08/2026
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated [...]
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
04/08/2026
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic [...]
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
04/08/2026
11 tissue, blood, and cerebrospinal fluid biomarkers reflecting the biological cascade of neurodegeneration and neuroinflammation in PD respond in concert to risvodetinib treatment in patients with early untreated [...]
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
04/08/2026
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga [...]
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
04/08/2026
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of [...]
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
04/08/2026
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development [...]
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
04/08/2026
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
04/08/2026
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~ SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), [...]
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
04/08/2026
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Exagen Inc. Reports Second Quarter 2026 Financial Results
04/08/2026
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million [...]

Pages